Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 2/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 3/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5279706 | 0.80 | PARP1 (0.40) | ROCK1MKNK1MKNK2CHEK2PARP1 | |
| SCHEMBL3340487 | 0.77 | MAPK14 (0.48) | ROCK1 | |
| SCHEMBL1140489 | 0.74 | MAPK14 (0.61) | — | |
| SCHEMBL1139701 | 0.74 | MAPK14 (0.61) | — | |
| SCHEMBL1140312 | 0.74 | MAPK14 (0.61) | — | |
| SCHEMBL5789403 | 0.70 | BTK (0.51) | IRAK4BTK | |
| SCHEMBL1139943 | 0.69 | MAPK14 (0.62) | — | |
| SCHEMBL20321274 | 0.67 | PARP1 (0.47) | ROCK1PARP1PRKCZ | |
| SCHEMBL5244617 | 0.66 | KDM4E (0.37) | MKNK2PARP1 | |
| SCHEMBL5274476 | 0.65 | CAPN1 (0.35) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682520-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-02-23 | — | — | EP | disclosed |
| US-7750154-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-20070043065-A1 | Amide derivatives | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1682520-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005042502-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043065-A1 | Amide derivatives | IL6, IL2, IL1B | IRAK4 217/4885ROCK1 2787/4885MKNK1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.